4DMedical Ltd's stock surged 12.26% during intraday trading on Monday, following the announcement of a significant regulatory milestone for the company.

The sharp increase came after 4DMedical secured approval from Australia's Therapeutic Goods Administration (TGA) for its CT:VQ lung imaging software. This clearance enables the commercial rollout of the technology nationwide through inclusion on the Australian Register of Therapeutic Goods (ARTG).

CT:VQ represents an innovative approach that generates ventilation-perfusion imaging from routine non-contrast chest CT scans. This technology eliminates the reliance on radiotracers or nuclear medicine infrastructure, potentially offering a more accessible and efficient diagnostic solution for lung conditions.